Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-88
SponsorBeth Israel Deaconess Medical Center
About this trial
There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.
Eligibility criteria
Qualifiers
Patients undergoing cardiac surgery under cardiopulmonary bypass.
Disqualifiers
Refusal to participate
Emergency surgery
Pre-existing heart block
Preexisting atrial fibrillation
Trial design
Treatments tested in this trial
- Gender
Treatment groups
500 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov